High Throughput Screening Market is predicted to reach USD 47.8 billion at a CAGR of 9.70% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global High Throughput Screening Market”.

The High Throughput Screening market is projected to register a CAGR of 9.70% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the global high throughput screening market— Corning Incorporated (US), Merck KGaA (Germany) is the second major player, followed by Tecan Trading AG (Switzerland), Agilent Technologies Inc (US), PerkinElmer Inc (US), Luminex Corporation (US), F. Hoffmann-La Roche Ltd (Switzerland), Promega Corporation (US), Beckman Coulter Inc (US), Hamilton Company (US), and others.

High Throughput Screening Market Highlights

The global High Throughput Screening market is accounted to register a CAGR of 9.70% during the forecast period and is estimated to reach USD 47.8 billion by 2032.

The growth of the global High Throughput Screening market is attributed to the growing genomic research activities is a significant driver for the global High Throughput Screening market. The growing genomic research activities is a significant driver in the global for high throughput screening market. In recent years, the field of genomic research has witnessed a tremendous surge in activities, driven by advancements in technology and increasing interest in understanding the human genome and its impact on health and disease. One of the key technologies revolutionizing this field is high-throughput screening, also known as next-generation screening (NGS). High-throughput screening enables researchers to sequence large volumes of DNA or RNA rapidly and cost-effectively, providing valuable insights into the genetic makeup of organisms. However, , the high Initial setup costs might hamper the market's growth in the forecast period.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of High Throughput Screening market

Segment Analysis

Based on product & service, the global high throughput screening market has been segmented into consumables, instruments, and software & services.

Based on technology, the global high throughput screening market has segmented into cell-based assays, Lab-on-a-Chip (LOC), ultra-high-throughput screening, label-free technology, and others.

Based on application, the global high throughput screening market has segmented into drug discovery, biochemical screening, cell & organ-based screening, and others

Based on end user, the global high throughput screening market has segmented into pharmaceutical and biotechnology companies, research institutes and organizations, and contract research organizations.

Regional Analysis

The global High Throughput Screening market, based on region, has been divided into North America, Europe, Asia-Pacific, and Middle East & Africa. The North America further includes US and Canada. The Europe includes countries namely Germany, France, UK, Italy, Spain, and Rest of Europe. The High Throughput Screening market in Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, and Rest of Asia-Pacific. Moreover, the Rest of the World comprises of Middle East, Africa, and Latin America.

The North America high-throughput screening market is comprised of North America and Latin America. Furthermore, North America consists of the US and Canada. The market growth has been driven by inorganic strategies to expand high-throughput screening (HTS) solutions to measure biochemical activities and identify binding interactions, which accelerate the timeline and reduce costs to identify lead drug candidates. For instance, in January 2023, Charles River Laboratories International, Inc. (US) acquired SAMDI Tech, Inc. (US), a leading provider of HTS solutions to expand HTS portfolio.

The growth of the European high-throughput screening market is driven by promoting HTS projects to accelerate the discovery of a lead molecule for a new drug. For instance, in March 2023, SCREENTECH opened under the complementary plan for biotechnology in Catalonia (Spain). This initiative prioritized the development of new projects based on the drug screening and drug-target interaction analysis platform at IRB Barcelona (US).

Moreover, the high indulgence of high-throughput screening start-up developers such as CN Bio (UK), Evosep (Denmark), Ovizio (Belgium), and Oxford Nanopore Technologies plc. (UK) through raising funding and incorporating innovation is creating huge opportunities for the region’s growth. For instance, in February 2023, CN Bio (UK) launched the PhysioMimix single-organ higher throughput (HT) system. The system was designed for earlier stages of the human liver model and through this large-scale drug discovery is possible.

The Asia-Pacific high-throughput screening market has shown immense growth in the last decade owing to increasing clinical trials. As per Pharma Intelligence UK Limited (UK), the Asia-Pacific (APAC) region accounted for 50% of clinical trial activity globally in 2021. Moreover, in APAC, China accounted for 45%, followed by Japan (21%), South Korea (13%), Australia (11%), and India (10%) in 2021.

The rest of the world is comprised of the Middle East, Africa, and Latin America. The region’s growth is attributed to the increasing prevalence of NCDs, which is creating opportunities for the biopharmaceutical and pharmaceutical industries to increase research for innovative drugs in the Africa region. As per the 2022 World Health Organisation (WHO) Noncommunicable Disease Progress Monitor, there are deaths accounted for by between 50% and 80% in the Africa region due to NCDs.

Key Findings of the Study

• The global high throughput screening market is expected to reach USD 47.8 billion by 2032 at a CAGR of 9.70% during the forecast period.


• The Europe region held the second largest market share of the global market, due to increasing prevalence of chronic diseases, the rising indulgence of start-ups working on advancements of the HTS system, and the development of new projects associated with the development of the HTS platform are propelling market growth.


• Corning Incorporated (US), Merck KGaA (Germany) is the second major player, followed by Tecan Trading AG (Switzerland), Agilent Technologies Inc (US), PerkinElmer Inc (US), Luminex Corporation (US), F. Hoffmann-La Roche Ltd (Switzerland), Promega Corporation (US), Beckman Coulter Inc (US), Hamilton Company (US) and others are the key players in the market.